Daily Anesthesiology Research Analysis
Analyzed 74 papers and selected 3 impactful papers.
Summary
Analyzed 74 papers and selected 3 impactful articles.
Selected Articles
1. In the gravid human uterus, oxytocin induces smooth muscle cell contraction via transient receptor potential vanilloid 4 channel activation.
Using gravid human myometrium, the authors demonstrate that oxytocin-induced calcium influx and contraction require TRPV4 channel activation and OXTR–TRPV4 proximity. Oxytocin-resistant uterine atony exhibited reduced glycosylated OXTR and diminished OXTR–TRPV4 interactions, implicating a novel mechanism and suggesting TRPV4-focused therapeutics.
Impact: This is a rigorous mechanistic study in human tissue that identifies TRPV4 as essential for oxytocin-induced uterine contraction and reveals disrupted OXTR–TRPV4 coupling in atony, opening therapeutic avenues.
Clinical Implications: For obstetric anesthesia and peripartum care, TRPV4 antagonists could be explored as tocolytics to prevent or treat preterm labor, while strategies enhancing OXTR–TRPV4 coupling may address oxytocin-resistant uterine atony and postpartum hemorrhage.
Key Findings
- TRPV4 and OXTR colocalize within <40 nm in gravid human myometrium and functionally interact.
- TRPV4 blockade or siRNA knockdown abolishes oxytocin-induced calcium influx and contraction; voltage-gated calcium channel blockade does not.
- Oxytocin-resistant uterine atony tissue shows reduced glycosylated OXTR and diminished OXTR–TRPV4 proximity ligation signals.
Methodological Strengths
- Use of primary human myometrial tissue and smooth muscle cells with multimodal validation (pharmacology, siRNA, proximity ligation).
- Direct comparison including tissue from oxytocin-resistant uterine atony patients.
Limitations
- Ex vivo/in vitro study without interventional clinical outcomes.
- Sample size and patient heterogeneity (e.g., parity, comorbidities) are not detailed; generalizability to laboring uterus requires study.
Future Directions: Evaluate TRPV4 modulators in translational models and early-phase trials; define biomarkers (e.g., OXTR glycosylation, OXTR–TRPV4 proximity) to stratify risk of atony or preterm labor.
Understanding the mechanism of oxytocin-induced uterine contractility is critical for addressing conditions at both extremes of the uterine contractility spectrum, preterm labour and uterine atony. We hypothesized that oxytocin induces extracellular calcium influx and uterine contraction through activation of the transient receptor potential vanilloid 4 (TRPV4) channel. To test this hypothesis, uterine tissue was obtained with informed consent from pregnant patients undergoing term, non-labouring caesarean delivery. In human myometrial tissue and smooth muscle cells in primary culture (mSMCs), TRPV4 and oxytocin receptor (OXTR) proteins colocalize at distances less than 40 nm. In mSMCs, both pharmacological blockade of TRPV4 and TRPV4 depletion via small interfering RNA prevent oxytocin-induced calcium influx and contraction. In contrast, voltage-gated calcium channel blockade does not diminish oxytocin-induced calcium transients. Pharmacological blockade of OXTR has no effect on TRPV4 agonist-induced calcium influx or contractility. In uterine tissue from patients with oxytocin-resistant uterine atony, there is a marked reduction in glycosylated OXTR expression and in proximity ligation between OXTR and TRPV4 compared with tissue from control patients with optimal postpartum contractility. Taken together, these findings demonstrate that in the gravid uterine smooth muscle, TRPV4 activation is required for oxytocin-induced uterine contraction. They also suggest reduced OXTR-TRPV4 protein-protein interaction as a novel pathophysiological mechanism underlying uterine atony in non-labouring parturients. These findings highlight the physiological importance of oxytocin signalling via the TRPV4 channel and may motivate the development of targeted, TRPV4-focused treatments to modulate uterine contractility. KEY POINTS: Oxytocin-induced contraction in smooth muscle cells from term pregnant human myometrium requires activation of the TRPV4 calcium channel. TRPV4 and oxytocin receptor (OXTR) colocalize at <40 nM and interact functionally in myometrial smooth muscle cells. TRPV4 antagonism or siRNA-mediated TRPV4 knockdown abolishes oxytocin-induced calcium influx and contractility. In patients with oxytocin-resistant uterine atony, glycosylated OXTR quantity and TR
2. Prussian blue nanoparticles targeting multiple PANoptosome-mediated PANoptosis for myocardial ischemia-reperfusion injury therapy.
Prussian blue nanoparticles, especially when platelet membrane-coated, inhibit PANoptosis by engaging multiple PANoptosome components, mitigating myocardial injury, remodeling, and hypertrophy after ischemia-reperfusion. Multi-omics and computational approaches corroborate disrupted PANoptosome assembly, ROS scavenging, and mitochondrial protection.
Impact: This work introduces a mechanistically grounded, multi-target nanotherapy that addresses convergent regulated cell death pathways in MIRI, a central perioperative and critical care problem.
Clinical Implications: While preclinical, the approach suggests a future perioperative cardioprotective strategy during cardiac surgery or high-risk ischemic states, warranting safety, dosing, and biodistribution studies before translation.
Key Findings
- PB nanoparticles bind RIPK1, ZBP1, and AIM2, disrupting PANoptosome assembly and concurrently suppressing pyroptosis, apoptosis, and necroptosis.
- Platelet membrane coating (PB@PM) enhances cardiac targeting and improves function, remodeling, and hypertrophy after ischemia-reperfusion.
- Multi-omics and simulations show ROS scavenging, mitochondrial improvement, and restored immune-inflammatory balance underpin efficacy.
Methodological Strengths
- Integration of single-nucleus human heart transcriptomics, molecular dynamics, imaging, and in vivo validation.
- Mechanistic targeting of convergent cell death pathways with demonstrated functional benefits.
Limitations
- Preclinical model; human safety, biodistribution, and long-term outcomes are unknown.
- Manufacturing scalability and reproducibility of platelet membrane coating require evaluation.
Future Directions: Conduct GLP toxicology, pharmacokinetics, and large-animal efficacy studies; explore perioperative delivery windows and combination with established cardioprotective measures.
The extensive crosstalk among pyroptosis, apoptosis, and necroptosis limits the efficacy of therapies targeting only one pathway. Here, we show that Prussian blue (PB) nanoparticles act as multi-target PANoptosis inhibitors by binding key PANoptosome components including RIPK1, ZBP1, and AIM2 through multimodal interactions, thereby concurrently suppressing pyroptosis, apoptosis, and necroptosis in myocardial ischemia-reperfusion injury (MIRI). Platelet membrane-coated PB nanoparticles (PB@PM) exhibit enhanced cardiac targeting and efficiently alleviate MIRI-induced cardiac dysfunction, adverse ventricular remodeling, and cardiomyocyte hypertrophy. Mechanistically, PB@PM disrupt PANoptosome assembly, scavenge reactive oxygen species, improve mitochondrial function, and restore immune-inflammatory homeostasis. By integrating single nucleus transcriptomics of human heart samples, molecular dynamics simulations, transcriptomics, medical imaging, and molecular validation, we systematically decipher the therapeutic mechanisms of PB-based PANoptosis inhibition. This study establishes an integrative multi-omics framework for exploring PANoptosis in cardiovascular diseases and provides a promising nanotherapeutic strategy for MIRI treatment.
3. Ciprofol versus propofol and the risk of hemodynamic adverse events: a meta-analysis with trial sequential analysis of randomized controlled trials.
Across 34 RCTs (5,162 patients), ciprofol reduced intraoperative hypotension versus propofol (RR 0.65) and lowered respiratory depression, injection pain, and hypoxemia, with similar anesthetic efficacy and a minimal increase in awakening time. Trial sequential analysis supported sufficiency for key outcomes, though overall certainty was low-to-moderate.
Impact: This synthesis directly informs anesthetic choice by quantifying hemodynamic advantages of ciprofol over propofol across diverse settings, addressing a common perioperative risk factor.
Clinical Implications: Consider ciprofol as an alternative to propofol in patients at risk of intraoperative hypotension, while recognizing heterogeneity and the low-to-moderate certainty; definitive head-to-head, high-quality trials are still needed.
Key Findings
- Ciprofol lowered intraoperative hypotension risk versus propofol (RR 0.65, 95% CI 0.57–0.73) across 34 RCTs (n=5,162).
- Secondary outcomes favored ciprofol: lower respiratory depression (RR 0.44), injection pain (RR 0.19), and hypoxemia (RR 0.62); awakening time slightly increased but likely clinically insignificant.
- Trial sequential analysis confirmed sufficient information size for hypotension and injection pain; GRADE certainty was low-to-moderate.
Methodological Strengths
- Comprehensive meta-analysis with subgroup analyses and trial sequential analysis.
- Randomized controlled trials included across diverse populations and procedures.
Limitations
- Heterogeneity across trials and low-to-moderate certainty of evidence; potential publication and regional biases.
- Secondary outcomes not uniformly reported; awakening time difference may be influenced by protocol variability.
Future Directions: Conduct large, CONSORT-compliant, head-to-head RCTs in high-risk surgical populations with standardized hemodynamic endpoints and longer-term outcomes.
INTRODUCTION: Intraoperative hypotension increases postoperative risks. Ciprofol, a novel anesthetic, has an onset and recovery profile comparable to propofol, but its potential superiority in mitigating intraoperative hypotension is unclear. This meta-analysis compares the incidence of intraoperative hypotension between ciprofol and propofol. METHODS: A comprehensive search of PubMed, Embase, and the Cochrane Library was performed up to December 10, 2025, to identify randomized controlled trials comparing ciprofol and propofol. Data were analyzed using RevMan and Stata. Subgroup analyses were conducted according to age, anesthetic dose, and type of procedure. Trial sequential analysis (TSA) was used to assess the robustness and sufficiency of the evidence. RESULTS: This meta-analysis of 34 trials (5,162 patients) found that ciprofol was associated with a significantly lower risk of intraoperative hypotension compared to propofol (RR = 0.65, 95% CI 0.57-0.73). This benefit was consistent across various subgroups, including different age groups, dose ranges, and procedure types. Ciprofol also demonstrated lower incidences of respiratory depression (RR = 0.44), injection pain (RR = 0.19), and hypoxemia (RR = 0.62), but was associated with a very small, likely clinically insignificant increase in awakening time;however, these findings are based on secondary outcomes and should be interpreted as exploratory. Trial sequential analysis confirmed sufficient sample size for the intraoperative hypotension and injection pain outcomes. The certainty of the evidence, assessed using the GRADE approach, was rated as low to moderate. CONCLUSIONS: Ciprofol was associated with a reduced incidence of intraoperative hypotension compared with propofol, with comparable anesthetic efficacy. Nevertheless, due to heterogeneity and overall low-to-moderate certainty of evidence, these findings should be interpreted with caution. Further large-scale, well-designed randomized controlled trials are warranted to validate these results and delineate the clinical benefits of ciprofol.